LongeVC has joined the $11.8 million pre-A financing round for Valink Therapeutics, a biotech company based in Cambridge, Massachusetts, that is developing bispecific antibody-drug conjugates (bsADCs) for oncology. The round was led by redalpine, with participation from Oxford Science Enterprises, RV Invest, p53 Invest, and Hoxton Ventures.
Valink's proprietary V-gate platform addresses key limitations of traditional ADCs by integrating novel targeting strategies with improved payload delivery. The company is currently advancing two oncology programs into preclinical development for solid tumor indications, including colorectal cancer.
Congratulations to CEO Arne Scheu and the entire Valink team.
Read the full press release here.
Valink's proprietary V-gate platform addresses key limitations of traditional ADCs by integrating novel targeting strategies with improved payload delivery. The company is currently advancing two oncology programs into preclinical development for solid tumor indications, including colorectal cancer.
Congratulations to CEO Arne Scheu and the entire Valink team.
Read the full press release here.